Ehud Grenadier, M.D., abstract author, CRF faculty member, and a faculty member at Rambam Hospital affiliated with the Technion – Israel Institute of Technology will present the "Optimizing Plaque Modification in Complex Lesions Utilizing the AngioSculpt Device: Acute and Long-Term Results from a Large Two-Center Registry."

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat high blood pressure, may play a role in reducing coronary plaque.

Alaskan Eskimos’ significantly higher rates of fatty artery plaque than the general U.S. population may be due to unhealthy lifestyle habits, researchers report in Stroke: Journal of the American Heart Association.

Amid growing evidence that the same abnormal clumping of proteins in Alzheimer’s disease also contributes to type-2 diabetes, scientists in New York are reporting discovery of a potent new compound that reduces formation of those so-called amyloid plaques.

The immune system's response against amyloid-beta, the protein that forms plaques in the brains of patients with Alzheimer's disease, appears to protect the brain from damage in early stages of the devastating neurological disorder.